D J Weidler
Overview
Explore the profile of D J Weidler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
80
Citations
595
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wagner J, Stoll R, Weidler D, Ayres J, Hallmark M, Sakmar E, et al.
J Pharmacokinet Biopharm
. 2010 Mar;
7(2):147-58.
PMID: 20218011
A blinded, four-treatment crossover study in 16 normal adult male volunteers compared plasma concentrations and urinary excretion of digoxin, measured by radioimmunoassay, after oral administration of soft gelatin capsule formulations...
2.
VanDenBerg C, Kazmi Y, Stewart J, Weidler D, Tenjarla S, Ward E, et al.
Am J Health Syst Pharm
. 2000 Jul;
57(11):1046-50.
PMID: 10876746
The absolute bioavailability and pharmacokinetics of three formulations of ondansetron hydrochloride 24 mg--an oral tablet, an intravenous solution, and an extemporaneous rectal suppository--were studied. Twelve healthy, nonsmoking volunteers (six men...
3.
Jann M, ZumBrunnen T, Tenjarla S, Ward Jr E, Weidler D
Pharmacotherapy
. 1998 Apr;
18(2):288-94.
PMID: 9545148
Study Objective: To compare the relative bioavailability of two 16-mg extemporaneously prepared suppository formulations with that of an 8-mg commercially available oral tablet. Design: Prospective, crossover bioavailability study. Setting: Inpatient...
4.
Sonnenberg G, Garg D, Weidler D, Dixon R, Jaber L, Bowen A, et al.
Ann Pharmacother
. 1997 Jun;
31(6):671-6.
PMID: 9184703
Objective: To investigate the metabolic effects and frequency of adverse events with 6 mg of glimepiride, a new oral sulfonylurea, given both in once- and twice-daily dosages to patients with...
5.
Ezekowitz M, Hossack K, Mehta J, Thadani U, Weidler D, Kostuk W, et al.
Am Heart J
. 1995 Mar;
129(3):527-35.
PMID: 7872184
The efficacy and safety of amlodipine, 10 mg, a new long-acting calcium antagonist, was compared with placebo in 103 patients with stable angina pectoris in a multicenter double-blind crossover study....
6.
Sweet C, Bradstreet D, Berman R, Jallard N, Saenz A, Weidler D
Am J Hypertens
. 1994 Dec;
7(12):1035-40.
PMID: 7702795
Losartan potassium (DuP 753), an orally active angiotensin II receptor antagonist, is metabolized to a more potent active metabolite, E-3174, which contributes to losartan's long duration of action. The acute...
7.
Hinson J, Hind I, Weidler D
J Pharm Sci
. 1994 Mar;
83(3):382-5.
PMID: 8207686
The pharmacokinetics of flosequinan and its active metabolite, flosequinoxan, were investigated following a single 100-mg oral dose in 10 patients with compromised hepatic function. Plasma and urine samples were collected...
8.
Jallad N, Cattan A, Weidler D
Int J Clin Pharmacol Ther Toxicol
. 1993 Aug;
31(8):376-81.
PMID: 8225682
Indomethacin, a nonsteroidal anti-inflammatory drug, may cause gastric mucosal damage as shown by fecal blood loss. A randomized, double-blind, placebo-controlled, parallel group study was conducted to determine the effects of...
9.
Gallo B, Hinson J, Weidler D
J Pharm Sci
. 1993 Mar;
82(3):282-5.
PMID: 8450423
The pharmacokinetics of flosequinan and its major active metabolite (BTS 53,554, 7-fluoro-1-methyl-3 methylsulfinyl-4-quinolone, 1) were investigated following a single oral dose of 100 mg of flosequinan in 20 patients with...
10.
Durel L, Hayashi P, Weidler D, Schneiderman N
J Clin Pharmacol
. 1992 Jun;
32(6):564-70.
PMID: 1634645
In a double-blind, crossover study, five white men with mild-to-moderate hypertension received placebo and fixed doses of atenolol, metoprolol, chlorthalidone, verapamil, and the combination of atenolol and chlorthalidone in a...